Mounton - Recently the possibility of labeling for Teva was discussed on this board and the chance of maybe a different pathway to approval. Why would the FDA trust MNTA and not TEVA regarding full characterization. The only reason I could think of would be MNTA's technology. Is there another reason I'am missing?
If not then rkrw's point of the FDA not trusting MNTA would also mean we have no greater or less chance for fully characterization then TEVA.
Market Data 
Markets 
AI
